AlzeCure

AlzeCure

Tillverkning av läkemedel

Stockholm, Stockholm County 6 720 följare

Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more

Om oss

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has a project in the field of pain in the early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se.

Bransch
Tillverkning av läkemedel
Företagsstorlek
11–50 anställda
Huvudkontor
Stockholm, Stockholm County
Typ
Publikt aktiebolag
Grundat
2016
Specialistområden
Drug Discovery Research, Alzheimer's Disease, Neurodegenerative Diseases och Pain Management

Adresser

Anställda på AlzeCure

Uppdateringar

  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    New anti-inflammatory data with NeuroRestore ACD856 at the Alzheimer's conference CTAD AlzeCure presentation at the Alzheimer's conference CTAD 2024 is now available in its entirety on the company's website. The presentation contains new preclinical data with the company's leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, and being prepared for phase II. ”These new data suggest that ACD856 may play an anti-inflammatory and immunoregulatory role, in addition to the memory-enhancing and disease-modifying effects we have previously presented, and demonstrate its potential to slow neurodegeneration in Alzheimer's and other diseases characterized by neuroinflammation," said Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure Pharma. “These new findings with NeuroRestore ACD856 have relevance not only for Alzheimer's, but also for other neurodegenerative diseases, such as Parkinson's and frontal lobe dementia. The results strengthen our commercial opportunities for ACD856, which we are now planning for phase II clinical studies in patients," said Martin Jönsson, CEO of AlzeCure Pharma. Read the press release: https://lnkd.in/dWj3SuZj The poster is available on AlzeCure's website https://lnkd.in/dUBj9yZ6 #alzecure #CTAD24 #ACD856 #alzheimers

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    CTAD 2024, Clinical Trials in Alzheimer’s Disease, has started. - We have so much to do in the fields of Alzheimer’s, so if we have seen tremendous development in the last five years with, for example improved diagnostics and anti-body treatments. This development has fueled the investments in the field, but the investment are still way to low, which is a shame, and bad health economically in a time where the societal cost are over one trillion US$, and its expected to triple in the coming thirty years. We at AlzeCure are proud to be here and present new data at the congress on our program NeuroRestore ACD856 which is presented by Cristina Parrado. Stay tuned on the data. #alzecure #ctad2024 #alzheimers #dementia #neurorestore

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    It has started … CTAD 2024 in Madrid #ctad2024 #alzecure

    Visa profilen för Martin Jönsson, grafik

    CEO at AlzeCure Pharma (Publ.)

    CTAD 2024, Clinical Trials in Alzheimer’s Disease, has started. - We have so much to do in the fields of Alzheimer’s, so if we have seen tremendous development in the last five years with for example improved diagnostics and anti-body treatments. This development has fueled the investments in the field, but the investment are still way to low, which is a shame, and bad health economically in a time where the societal cost for Alzheimer's are over one trillion US$, and are expected to triple in the coming thirty years. We at AlzeCure are proud to be here and present new data at the congress on our program NeuroRestore ACD856 which is presented by Cristina Parrado. Stay tuned on the data. #alzecure #ctad2024 #alzheimers #dementia #neurorestore

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    Nice that all those years of medicinal chemistry efforts paid off and led to the discovery of ACD137, a promising molecule with analgesic effects in models of neuropathic and nociceptive pain.

    Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    New positive data for the TrkA-NAM pain project against osteoarthritis AlzeCure has obtained new positive preclinical efficacy data supporting the continued development of the candidate drug ACD137 within the TrkA-NAM program. The new in vivo data, obtained in a rat model of osteoarthritis (OA) of the knee, show significant pain relief in both movement-induced and evoked pain as well as a significant anti-inflammatory effect. The analgesic effect of ACD137 is in line with the effect of the anti-NGF antibody Tanezumab, which have in several clinical trials demonstrated significant and robust pain relief, showing that ACD137 can reach the same efficacy as Tanezumab at the investigated doses. ACD137 treatment also significantly improved a number of cartilage and knee joint structural parameters suggesting a protective effect on knee-joint function in a model of osteoarthritis. Repeated administration of ACD137 for 18 days was well tolerated and there were no clinical symptoms or histopathological findings of rapidly progressing OA (RPOA), a problematic side effect observed for anti-NGF antibodies, including Tanezumab, nor were any effects seen on neuronal ganglia. "Interest in TrkA-NAM has increased further after Asahi Kasei recently started its phase 2b study with AK-1830 against knee osteoarthritis, which validates AlzeCure's project, where we have developed molecules that are even more potent and selective than AK-1830," said Martin Jönsson, CEO of AlzeCure Pharma. “The combination of potent analgesic effects and anti-inflammatory action could provide significant pain relief for patients, and also opens up other possible indications”. Read the press release https://lnkd.in/dRQGw-az #alzecure #TrkANAM #ACD137 #osteoarthritis #AK1830

  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    New positive data for the TrkA-NAM pain project against osteoarthritis AlzeCure has obtained new positive preclinical efficacy data supporting the continued development of the candidate drug ACD137 within the TrkA-NAM program. The new in vivo data, obtained in a rat model of osteoarthritis (OA) of the knee, show significant pain relief in both movement-induced and evoked pain as well as a significant anti-inflammatory effect. The analgesic effect of ACD137 is in line with the effect of the anti-NGF antibody Tanezumab, which have in several clinical trials demonstrated significant and robust pain relief, showing that ACD137 can reach the same efficacy as Tanezumab at the investigated doses. ACD137 treatment also significantly improved a number of cartilage and knee joint structural parameters suggesting a protective effect on knee-joint function in a model of osteoarthritis. Repeated administration of ACD137 for 18 days was well tolerated and there were no clinical symptoms or histopathological findings of rapidly progressing OA (RPOA), a problematic side effect observed for anti-NGF antibodies, including Tanezumab, nor were any effects seen on neuronal ganglia. "Interest in TrkA-NAM has increased further after Asahi Kasei recently started its phase 2b study with AK-1830 against knee osteoarthritis, which validates AlzeCure's project, where we have developed molecules that are even more potent and selective than AK-1830," said Martin Jönsson, CEO of AlzeCure Pharma. “The combination of potent analgesic effects and anti-inflammatory action could provide significant pain relief for patients, and also opens up other possible indications”. Read the press release https://lnkd.in/dRQGw-az #alzecure #TrkANAM #ACD137 #osteoarthritis #AK1830

  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    I will attend CTAD Looking forward to attend CTAD Where we will present new data on NeuroRestore ACD856. NeuroRestore* is developed to improve memory and learning capabilities in patients with Alzheimer’s and other cognitive disorder, and is a Trk-PAM increasing BDNF and NGF signaling, and has also shown potential with regard to disease modifications. - Join me & let’s meet up at CTAD in Madrid. https://lnkd.in/dKtf_nK *) https://lnkd.in/e6BR563C #alzecure #partnering #CEO #CTAD24 #alzheimers #neurorestore

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    I will attend CTAD Looking forward to attend CTAD Where we will present new data on NeuroRestore ACD856. NeuroRestore* is developed to improve memory and learning capabilities in patients with Alzheimer’s and other cognitive disorder, and is a Trk-PAM increasing BDNF and NGF signaling, and has also shown potential with regard to disease modifications. - Join me & let’s meet up at CTAD in Madrid. https://lnkd.in/dKtf_nK *) https://lnkd.in/e6BR563C #alzecure #partnering #CEO #CTAD24 #alzheimers #neurorestore

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    Looking forward to attend Bioscience where Pontus will present AlzeCure and our ability to develope first in class molecules for several disease areas. - Come and join. #alzecure #neuroscience #bioscience2024

    Visa organisationssidan för AlzeCure, grafik

    6 720 följare

    The company’s co-founder and Head of Discovery and Research, Dr. Pontus Forsell, will present at the 12th annual Bioscience conference, held at Life City in Stockholm, Sweden. Alzecure Pharma, as a company that has progressed several first in class molecules in different areas of CNS and pain from discovery to clinic, is invited to present the key factors behind its R&D achievements at the Bioscience partnering conference. Dr. Forsell’s presentation, titled How to build an R&D organization with a diverse CNS drug discovery pipeline, will be held on November 7 at 11.20 am. Bioscience 2024 is an international partnering event, organized by Life Science Sweden, where delegates from both academia and the pharmaceutical industry gather. The event takes place at Life City, the new venue which is part of Stockholm's fast-growing hub for life sciences, located next to Karolinska Institutet. To the press release: https://lnkd.in/dnBmkpFP For program and registration, please see: https://lnkd.in/deaArUf8 Time: 08.00-16.00 CEST, November 7, 2024 Venue: Life City, Solnavägen 3H, Stockholm, Sweden #alzecure #CNS #alzheimerfonden #Lifescience # Discovery #Research #LifeScienceSweden

    • Ingen alternativ bildtext i den här bilden

Liknande sidor